Today: 30 June 2026
Browse Category

NASDAQ:OCUL 6 December 2025 - 30 May 2026

Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding

Oculis Stock Shock: Eye-Drop Trial Miss Sends Shares Sliding

Oculis Holding AG shares fell sharply on Friday after the Swiss eye-drug developer said two late-stage trials of its OCS-01 eye drops failed to meet their main goal in diabetic macular edema, a diabetes-linked swelling in the retina that can damage sight. The company said it does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug in that indication. The stock closed regular trading on Nasdaq at $22.70, down 23.4%, with volume around 2.76 million shares, far above its average volume of about 473,000. MarketWatch showed the shares at $18.35 in after-hours trading at 4:50 p.m. EDT, a further 19.2% drop from the close.
30 May 2026
··
Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

As of the close on Friday, December 5, 2025, Ocular Therapeutix, Inc. finished regular trading at $12.58 per share, up about 1.2% on the day, with after‑hours quotes on some platforms briefly touching the $14 area. StockAnalysis+1 The move caps a strong week: on Thursday the stock jumped roughly 12.3% to around $12.87, well above its recent averages, as traders responded to a new regulatory strategy for its lead retina drug AXPAXLI and fresh analyst commentary. MarketBeat+1
6 December 2025
···

Stock Market Today

  • Dycom Industries (DY) gains 12.6% in 12 weeks on momentum signals
    June 30, 2026, 10:23 AM EDT. Dycom Industries (DY) has put up a 12.6% price move over the past 12 weeks and is up 9.1% in the last month, showing steady price momentum for trend-focused investors. Shares are now trading at 96.2% of their 52-week range, which could point to a possible breakout. The stock carries a Zacks Rank #2 (Buy) and sits in the top 20% for earnings estimate revisions and earnings surprises-usually big for short-term swings. It also holds an Average Broker Recommendation of #1 (Strong Buy), often seen as a gauge of positive sentiment. This mix of price strength and solid analyst ratings is keeping DY on the radar of traders looking for momentum setups.
Go toTop